On Monday, in the course of current trade, Shares of Hartford Financial Services Group Inc (NYSE:HIG), climbed 0.62%, and is now trading at $47.89.
Hartford Financial Services Group stated core earnings of $389 million for the three months ended June 30, 2015 (second quarter 2015), an enhance of $245 million from $144 million in second quarter 2014. The enhance was primarily due to improved underwriting results in Property & Casualty (P&C) and higher core earnings in Talcott Resolution. The improvement in P&C underwriting results comprised of better current accident year loss results and lower unfavorable preceding year loss and loss adjustment expense reserve development (PYD) related to the company’s annual ground-up asbestos and environmental (A&E) study. Higher core earnings in Talcott Resolution were due to a $48 million tax benefit and the impact of strong investment income, principally from higher limited partnership and other alternative investments (LPs).
Second quarter 2015 core earnings per diluted share was $0.91 contrast with $0.31 in second quarter 2014, reflecting raised core earnings as well as the 9% decrease in weighted average diluted common shares outstanding over the past 12 months due to the company’s equity repurchases.
The Hartford Financial Services Group, Inc., through its auxiliaries, provides insurance and financial services to individual and business customers primarily in the United States. The company’s Commercial Lines segment offers workers compensation, property, automobile, marine, umbrella, liability, and livestock coverages, in addition to customized insurance products and risk administration services, counting professional liability, bond, and specialty casualty coverages.
During mid-morning trade, Shares of Delphi Automotive PLC (NYSE:DLPH), dipped -0.76%, and is now trading at $77.56.
Delphi Automotive, stated second quarter 2015 U.S. GAAP earnings from ongoing operations of $1.21 per diluted share. Not taking into account special items, second quarter earnings from ongoing operations totaled $1.34 per diluted share.
Second Quarter Highlights Comprise:
- Revenue of $3.9 billion, up 4% adjusted for currency exchange and commodity movements
- S. GAAP diluted earnings per share from ongoing operations of $1.21
- Not taking into account special items, earnings from ongoing operations of $1.34 per diluted share
- Adjusted Operating Income of $526 million
- Adjusted Operating Income margin of 13.6%, up 80 basis points
- Generated $514 million of cash from ongoing operations
- Closed the sale of wholly owned Thermal Systems business to MAHLE; received net cash proceeds of $660 million; recognized after-tax gain on divestiture of $285 million
Delphi Automotive PLC, together with its auxiliaries, manufacturers vehicle components; and provides electrical and electronic, powertrain, safety, and thermal technology solutions to the automotive and commercial vehicle markets worldwide. The company operates through four segments: Electrical/Electronic Architecture, Powertrain Systems, Electronics and Safety, and Thermal Systems.
Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), during its Monday’s current trading session gained 0.28%, and is now trading at $0.182.
Aeterna Zentaris, declared it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the development of a new class of potential cancer therapies.
The MAPK pathway represents a prime target for therapeutic intervention in cancer. Recently approved compounds demonstrate noteworthy antitumor activities and survival benefits for B-Raf and Mek inhibitors. Erk inhibitors may be preferred agents in tumors with aberrant MAPK pathway activity, e.g. in tumors with mutated or wildtype B-Raf, mutated or wildtype ras, and in tumors with attained resistance to Raf and Mek inhibitors.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Finally, Textron Inc. (NYSE:TXT), lost -0.27% Monday.
Bell Boeing, a planned alliance between Bell Helicopter, a Textron [NYSE: TXT] company, and Boeing [NYSE: BA], was awarded a U.S. Navy contract recently for five Bell Boeing V-22 Osprey tiltrotor aircraft to be delivered to Japan, marking the first sale of the aircraft through the U.S. government’s foreign military sales program.
The contract for the Block C aircraft comprises support, training, and equipment. The versatile V-22 tiltrotor will allow Japan’s Ground Self-Defense Force greatly improved capabilities, while providing an ideal platform for relief efforts in response to natural disasters.
Textron Inc. operates in the aircraft, defense, industrial, and finance businesses worldwide. It operates through five segments: Textron Aviation, Bell, Textron Systems, Industrial, and Finance.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
